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BACKGROUND: Because there is limited population-based evidence supporting the comparative effectiveness of lap-
aroscopic radical nephrectomy (LRN) after its widespread adoption, we compared trends in hospital-based outcomes
among patients with kidney cancer treated with LRN or open radical nephrectomy (ORN). METHODS: Using linked
SEER-Medicare data, the authors identified patients with kidney cancer who were treated with LRN or ORN from
2000 through 2005. The authors measured 4 primary outcomes: intensive care unit (ICU) admission, prolonged
length of stay, 30-day hospital readmission, and in-hospital mortality. The authors then estimated the association
between surgical approach and each outcome, adjusting for patient demographics, tumor characteristics, and year of
surgery. RESULTS: The authors identified 2108 (26%) and 5895 (74%) patients treated with LRN and ORN, respec-
tively. Patients treated with LRN were more likely to be white, female, of higher socioeconomic position, and to have
tumor sizes of 4 cm (all P < .05). The adjusted probability of ICU admission and prolonged length of stay was 41%
and 46% lower, respectively, for patients undergoing LRN (P < .001). Although uncommon for both groups, the
adjusted probability of in-hospital mortality was 51% higher (2.3% vs 1.5%, P ¼ .04) for patients treated with a laparo-
scopic approach. CONCLUSIONS: At a population level, patients treated with LRN have a lower likelihood of ICU
admission and prolonged length of stay, supporting the convalescence benefits of laparoscopy. In-hospital mortality,
however, was higher among patients treated with LRN. The latter finding suggests a potentially unanticipated conse-
quence of this technique and highlights the need for long-term monitoring during and after the widespread adoption
of new surgical technologies. Cancer 2011;117:4184–93. VC 2011 American Cancer Society.
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In contrast to pharmaceuticals where novel agents undergo rigorous assessment of safety and efficacy before introduction
into clinical practice, the adoption of new surgical techniques and technology is often driven by perceived (rather than pro-
ven) clinical benefit, patient and surgeon demand, and economic considerations.1-3 Accordingly, it is not uncommon for
diffusion of surgical innovation to outpace the generation of evidence supporting its safety and effectiveness in diverse clin-
ical settings.1,4 In some cases, this paradox can expose patients to unanticipated risks associated with widespread imple-
mentation of new surgical techniques. Illustrating this point, evaluation of patient outcomes following the widespread
adoption of laparoscopic cholecystectomy revealed higher than expected rates of potentially lethal bile duct injuries.5-7
Likewise, unanticipated adverse outcomes were identified in postdiffusion appraisals of extracranial-intracranial arterial
bypass surgeries among patients at risk for ischemic stroke.8 Given these concerns, there is now growing support for efforts
aimed at long-term monitoring of the safety and comparative effectiveness of novel surgical techniques even after their
widespread implementation in both academic and community practice.4
In urological oncology, laparoscopic radical nephrectomy (LRN) is now widely accepted as the standard of care for
many patients requiring complete kidney removal for renal cell carcinoma. When compared with open radical nephrec-
tomy (ORN), the available evidence indicates that LRN provides equivalent cancer control while affording an easier and
more rapid convalescence.9-11 Importantly, however, the actual empirical data supporting this conclusion come mainly
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from case series reported by innovators and early adopters.
Moreover, because there is a substantial learning curve
associated with this technique,10,12 it can be argued that
LRN represents a quintessential procedure for which
additional data are needed to clarify whether the compara-
tive benefits of LRN have been achieved at a population-
level and/or whether unintended consequences have
occurred during its widespread adoption.
In this context, we used linked Surveillance, Epide-
miology, and End Results (SEER)-Medicare data to mea-
sure and compare longitudinal trends for the following
hospital-based outcomes among patients with renal cell
carcinoma treated with LRN versus ORN: 1) intensive
care unit (ICU) admission, 2) length of stay (LOS), 3) 30-
day hospital readmission, and 4) in-hospital mortality. By
evaluating these outcomes during the period of wide-
spread adoption, we can begin to better understand the
long-term safety and comparative effectiveness of this
now common surgical procedure.
MATERIALS AND METHODS
Data Source
We used linked data from the National Cancer Institute’s
Surveillance, Epidemiology, and End Results (SEER)
Program and the Centers for Medicare and Medicaid
Services (Medicare) to identify patients diagnosed with
incident kidney cancer from 2000 through 2005. Based
on our prior work, this corresponds with a period of wide-
spread adoption of LRN by the urologic community.13
SEER is a population-based cancer registry that collects
data on incidence, treatment, and mortality. The demo-
graphic composition, cancer incidence, and mortality
trends in the SEER registries are representative of the
entire US population.14 The Medicare Program provides
primary health insurance for 97% of the US population
aged 65 years.15 Successful linkage with Medicare
claims is achieved for over 90% of Medicare patients
whose cancer-specific data are tracked by SEER.15
Cohort identification and assignment
of surgical procedures
After identifying 12,031 patients diagnosed with nonuro-
thelial, nonmetastatic, kidney cancer from 2000 through
2005, we searched inpatient (Medicare Provider Analysis
and Review file, based on International Classification of
Diseases, 9th revision, Clinical Modification [ICD-9])
and physician claims (Carrier Claims file, based on Cur-
rent Procedural Terminology [CPT] and ICD-9 codes) to
identify kidney cancer-specific diagnosis and procedure
codes. We then used a validated, claims-based algorithm to
determine the specific surgical procedure for each subject in
our cohort.16 Using this approach, we assigned each patient
to 1 of 4 procedures: open radical nephrectomy (ORN),
open partial nephrectomy (OPN), laparoscopic radical ne-
phrectomy (LRN), or laparoscopic partial nephrectomy
(LPN). We then limited our cohort to patients treated with
unilateral LRN or ORN as primary treatment for localized
or regional kidney cancer (n¼ 8003).
Patient-Level Covariates
For each patient in the study cohort, we used SEER data to
determine demographic and cancer-specific information,
including age, sex, SEER registry, race/ethnicity, marital
status, tumor size, and tumor stage. Based on patients’ zip
codes, we also assigned patients to 1 of 3 socioeconomic
strata.17 We measured pre-existing comorbidity by using a
modification of the Charlson index to identify comorbid
conditions (including diabetes, renal insufficiency, and
cardiovascular disease) from inpatient and physician claims
that were submitted during the 12 months before the index
admission for kidney cancer surgery.18
Primary Outcomes
We assessed the following hospital-based outcomes for
patients treated with LRN or ORN: 1) ICU admission, 2)
LOS, 3) 30-day hospital readmission, and 4) in-hospital
mortality. Our claims-based definitions for the above out-
come measures were adapted from the published literature.
Briefly, we identified ICU admission through billing codes
that indicate time spent in an ICU setting (including inter-
mediate and coronary care units).19,20 As a secondary step,
we verified the use of ICU care based on specific ICU
charges and variables indicating ICU day counts greater
than 0 during the index hospital admission.20,21 We
defined LOS as the duration between the admission date
and final discharge date for the index hospitalization (which
included transfers to another acute care hospital). We then
used LOS greater than the 90th percentile for all admissions
as our definition for prolonged LOS.22We defined hospital
readmissions based on the presence of a subsequent claim
for inpatient care (excluding transfers and claims for skilled
nursing facilities or inpatient rehabilitation [DRG 462])
within 30 days of discharge from the index hospitaliza-
tion.23 Finally, we defined in-hospital mortality as death
during the index hospitalization.
Primary statistical analyses
We used chi-square tests to evaluate the association
between surgical approach (LRN vs ORN) and patient-
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level covariates. We calculated annual rates of ICU admis-
sion by dividing the number of events for patients treated
with LRN or ORN, respectively, by the total number of
patients treated with each technique. We determined the
mean and median length of stay by surgical approach for
each year. For assessing rates of readmissions, our numera-
tor was the number of readmissions for patients treated
with LRN or ORN, and our denominator was the num-
ber of patients treated with either LRN or ORNwho were
discharged alive from the index hospitalization. Annual
rates of in-hospital mortality were calculated in the same
manner as annual rates of ICU admission. We then
assessed for each procedure longitudinal trends in rates of
ICU admission, LOS, 30-day hospital readmission, and
in-hospital mortality using the Student t test or Mantel-
Haenszel chi-square test as appropriate.
Next, we fit multivariate logistic regression models
to estimate the association between type of surgery and
each of our primary outcomes. We treated ICU admis-
sion, prolonged LOS, 30-day hospital readmission, and
in-hospital mortality as binary (ie, yes/no) variables. We
implemented generalized estimating equations to account
for clustering of patient outcomes within hospitals, and
we adjusted our models for patient characteristics (ie, age,
race, sex, marital status, socioeconomic position, and pre-
existing comorbidity), cancer severity (ie, size, stage), and
year of surgery. From our models, we then calculated pre-
dicted probabilities of each hospital-based outcome for
LRN and ORN, assuming similar patient characteristics,
tumor severity, and year of surgery.
Sensitivity Analyses
We then performed several sensitivity analyses to assess
the robustness of our primary findings. First, to determine
whether geographic variation accounted for our findings,
we repeated our analyses after we stratified the study
cohort by SEER registry. Second, recognizing the poten-
tial implications for postoperative morbidity and mortal-
ity, we refit our models after excluding patients with
missing data for tumor size (n ¼ 157) and comorbidity
(n¼ 243). Third, recognizing the lack of granular staging
information available through SEER, we also refit our
models after applying the following exclusion criteria: 1)
patients with regional disease, 2) patients with tumors
larger than 7 cm, 3) patients with regional disease and
tumors larger than 7 cm, and 4) patients with regional dis-
ease and tumors larger than 4 cm. Fourth, to account for
differences in hospitals that offer only 1 surgical approach,
we also refit our models after limiting the sample to
patients treated in hospitals that performed both LRN
and ORN from 2000 through 2005. Fifth, we repeated
our analyses after excluding patients (n¼ 62) with ICD-9
diagnosis codes indicating a conversion from laparoscopic
to open surgery, as these patients were exposed to both
surgical approaches. Finally, to assess consistency over
time, we repeated our analyses based on a larger sample
that also included patients treated with LRN or ORN
from 1995 through 1999.
Secondary Statistical Analyses
Next, we performed additional analyses designed to clarify
the observed relations between surgical approach and our
primary outcomes. First, using methods described previ-
ously,24,25 we determined the annual kidney cancer-spe-
cific case-volume for each surgeon and hospital and
performed Mantel-Haenszel chi-square tests to examine
the relation between case-volume and each primary out-
come, stratified by surgical approach. To clarify the
observed relation between surgical approach and in-hospi-
tal mortality, we then measured and compared the fre-
quency of postoperative complications—both overall and
among those patients who experienced in-hospital
deaths—for patients treated with LRN versus ORN.
Guided by validated methods developed by the Compli-
cations Screening Program, we used specific ICD-9 codes
to specifically identify complications related to gastroin-
testinal injury, myocardial infarction, respiratory failure,
wound infection, hemorrhage, venothromboembolism,
and accidental puncture or laceration, among other diag-
noses.26-28 As a final step, we identified blood transfusions
through billing codes and compared the frequency of
transfusions by procedure (both overall and among those
patients who experienced in-hospital mortality).
All statistical testing was 2-sided, completed using
computerized software (SAS version 9.2; SAS Institute,
Cary, North Carolina), and carried out at the 5% signifi-
cance level. This study was deemed exempt by the Univer-
sity of Michigan Medical School Institutional Review
Board.
RESULTS
We identified 2108 (26%) patients treated with LRN and
5929 (74%) patients treated with ORN from 2000
through 2005. As presented in Table 1, patients under-
going LRN were more likely to be white, female, and of
higher socioeconomic status (all P< .02). Patients treated
with LRN were also more likely to have a tumor 4 cm
and to have had surgery after 2002 (all P< .001).
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Figures 1 through 4 present temporal trends for
each outcome stratified by surgical approach. Over the
entire study interval, patients treated with LRN had a
median length of stay of 4 days (range, 1-67 days) whereas
patients treated with ORN had a median length of stay of
5 days (range, 3-144 days). Only mean LOS and 30-day
hospital readmissions for patients treated with LRN
changed significantly (ie, decreased) during the study
interval (P< .05).
After we adjusted for measurable patient and tumor
characteristics, as well as year of surgery, patients treated
with LRN were significantly less likely to require ICU
admission (odds ratio [OR], 0.49; 95% confidence inter-
val [CI], 0.43-0.55) and to have a prolonged LOS (OR,
0.52; 95% CI, 0.42-0.64). The likelihood of readmission
did not differ significantly between the treatment groups
(OR, 1.05; 95% CI, 0.88-1.26). Conversely, during the
entire study interval, patients treated with LRN had a
significantly higher risk of in-hospital mortality (OR,
1.54; 95%CI, 1.02-2.32).
Figure 5 depicts these findings further by present-
ing model-predicted probabilities for each outcome by
Table 1. Patient Demographics, Tumor Severity,
and Year of Surgery
LRN ORN P
No. of Patients 2108 5895
% %
Age, y











Male 55.0 58.0 .018
Female 45.0 42.0
Married
Yes 61.3 61.7 .761
No 38.7 38.3
Socioeconomic status (tertiles)








£4 cm 45.8 36.1 <.001
4-7 cm 39.2 36.4
>7 cm 15.0 27.5
Tumor stage
Local or in situ 80.1 72.5 <.001
Regional 19.9 27.5
Year of surgery
2000-2002 25.7 55.3 <.001
2003-2005 74.3 44.7
Abbreviations: ORN, open radical nephrectomy; LRN, laparoscopic radical
nephrectomy.
Figure 1. Temporal trends were assessed by Mantel Haenszel
chi-square tests of intensive care unit (ICU) admission during
index hospitalization by surgical approach from 2000 to
2005. Abbreviations: LRN, laparoscopic radical nephrectomy;
ORN, open radical nephrectomy.
Figure 2. Temporal trends of mean length of stay of index
hospitalization by surgical approach from 2000 to 2005
were assessed by linear regression and Student t tests.
Abbreviations: LRN, laparoscopic radical nephrectomy; ORN,
open radical nephrectomy.
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treatment group. The probability of ICU admission and
prolonged LOS was 41% and 46% lower, respectively, for
patients undergoing LRN versus ORN. In contrast,
although still uncommon, the adjusted probability of in-
hospital mortality was 51% higher for patients treated
with a laparoscopic versus open approach. These findings
did not change substantively when we refit our models af-
ter stratifying by SEER registry, excluding patients with
missing data or laparoscopic conversions, excluding
patients with regional disease and/or larger tumor size,
limiting our samples to patients from hospitals where
both procedures were performed, or including patients
treated from 1995 through 1999.
Table 2 describes the relation between case-volume
(ie, surgeon and hospital) and each hospital-based out-
come. Higher-volume surgeons and hospitals had lower
rates of ICU admission and prolonged LOS for both
surgical approaches, whereas 30-day readmission was
associated only with hospital case-volume for patients
treated with ORN (P< .05). Among patients undergoing
LRN, those treated by surgeons in the highest nephrec-
tomy-volume quartile had significantly lower in-hospital
mortality than patients whose surgeons were in the lowest
volume quartile (1.1% vs 2.8%, P ¼ .049). Likewise,
patients who underwent LRN at a hospital in the highest
kidney cancer case-volume quartile had lower mortality
than those treated at hospitals in the lowest quartile (1.3%
vs 3.5%, P ¼ .011). In contrast to the laparoscopic
approach, we observed no variation by volume strata for
in-hospital mortality among patients treated with ORN
(P> .20).
To better understand the observed relation between
surgical approach and in-hospital mortality, we also
assessed the frequency of postoperative complications and
blood transfusions after laparoscopic versus open radical
nephrectomy (Fig. 6). Among the entire cohort, patients
treated with LRN had fewer postoperative complications
and blood transfusions than those treated with ORN
(31.7% vs 38.8%, P < .001; 1.9% vs 4.2%, P < .001,
respectively). However, among the subset of patients who
Figure 4. Temporal trends were assessed by Mantel-Haenszel
chi-square tests of in-hospital mortality during index hospital-
ization by surgical approach from 2000 to 2005. Abbrevia-
tions: LRN, laparoscopic radical nephrectomy; ORN, open
radical nephrectomy.
Figure 3. Temporal trends were assessed by Mantel-Haenszel
chi-square tests of 30-day hospital readmission by surgical
approach from 2000 to 2005. Abbreviations: LRN, laparo-
scopic radical nephrectomy; ORN, open radical nephrectomy. Figure 5. Predicted probabilities of intensive care unit (ICU)
admission, prolonged length of stay (LOS), 30-day hospital
readmission, and in-hospital mortality are shown according
to surgical approach. Prolonged LOS is defined as LOS
greater than the 90th percentile. Predicted probabilities are
derived from generalized estimating equation models adjust-
ing for patient demographics, Charlson comorbidity index,
tumor size and stage, and year of surgery.
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died during the index hospitalization, rates of complica-
tions and blood transfusions did not differ by surgical
approach (97.6% LRN vs 93.6%ORN, P¼ .435; 14.3%
LRN vs 6.5%ORN, P¼ .190).
DISCUSSION
It is widely accepted that for patients with early stage kid-
ney cancer, laparoscopic radical nephrectomy produces
equivalent oncologic outcomes with the concurrent bene-
fits of decreased pain and easier overall recovery.9-11
Accordingly, the recently released American Urological
Association (AUA) Guidelines advocate for laparoscopy
as the preferred surgical approach for most patients under-
going radical nephrectomy.29 However, the evidence for
this recommendation is based mainly on the experience
and outcomes reported by early innovators and adopters
with established expertise in this advanced surgical tech-
nique. In fact, there are limited data assessing whether or
not the dissemination of LRN is translating these benefits
to a broader population of patients with renal cell
carcinoma.
Among a nationally representative sample of Medi-
care beneficiaries, we observed that patients treated with
laparoscopic versus open radical nephrectomy were signif-
icantly less likely to receive postoperative care in an ICU
or to have a prolonged LOS during a period of time
(2000-2005) that corresponded with escalating adoption
of LRN throughout the urological community.13 More-
over, among patients treated with LRN, average LOS and
rates of readmission decreased significantly during the
study interval and may now be lower than for patients
treated with ORN. Taken together, these comparative
trends support the convalescence benefits of LRN at a
population level.
Although the translation of these benefits to real-
world practice is encouraging, it is worth recognizing that
the average LOS and absolute rates of ICU admission
among Medicare beneficiaries are substantively higher
than those reported in most case series.9,10,30 In particular,
reports from centers with extensive laparoscopic experi-
ence suggest that a shorter LOS can be achieved on a
national basis for patients treated with LRN.9,10 As for the
Table 2. Procedure-Specific Outcomes According to Case-Volume Strata
Volume Quartiles Bottom Second Third Top P
% % % %
Hospital case-volume
ICU admission 53.2 40.9 35.2 25.3 <.001
ORN 56.7 45.2 39.7 30.1 <.001
LRN 35.7 29.4 26.5 16.4 <.001
Prolonged LOS 13.2 12.0 9.3 9.7 <.001
ORN 14.1 13.8 10.7 11.9 .011
LRN 9.1 7.0 5.6 5.5 .026
Readmission 11.3 11.5 10.5 9.3 .030
ORN 11.6 11.6 10.0 9.2 .018
LRN 9.5 11.3 12.2 9.3 .816
In-hospital mortality 2.2 1.9 1.0 1.6 .061
ORN 1.9 1.7 0.9 1.8 .409
LRN 3.5 2.4 1.5 1.3 .011
Surgeon case-volume
ICU admission 45.0 44.4 38.0 28.1 <.001
ORN 48.3 49.1 41.6 34.5 <.001
LRN 30.0 28.2 27.9 19.3 <.001
Prolonged LOS 12.7 12.7 10.6 8.7 <.001
ORN 13.6 14.4 11.7 11.6 .037
LRN 8.6 6.5 7.5 4.6 .009
Readmission 11.0 10.5 11.3 9.4 .227
ORN 11.0 10.6 11.3 9.3 .350
LRN 11.1 10.1 11.5 9.4 .478
In-hospital mortality 1.8 1.8 1.5 1.4 .224
ORN 1.6 1.9 1.3 1.6 .716
LRN 2.8 1.4 2.2 1.1 .049
Abbreviations: ICU, intensive care unit; LOS, length of stay; ORN, open radical nephrectomy; LRN, laparoscopic radical
nephrectomy.
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relatively higher rates of intensive care use, 1 explanation
is that we include in our definition of ICU utilization
patients admitted to intermediate and/or coronary care
units. Although these settings may not be ICUs in the
most traditional sense, they nonetheless provide higher-
intensity and higher-cost care and, therefore, represent
clinically important outcomes. Moreover, there is a strong
volume-outcome relation with LOS and ICU utilization,
and other investigators have noted a similar contrast
between case series and population-based data with
respect to the frequency of these outcomes.31 Accordingly,
although LRN undoubtedly provides many patients with
an easier convalescence, it appears that there is an oppor-
tunity for even greater population-level efficiency in the
postoperative care of these patients.
Although they generally enjoy a more rapid and less
intense recovery, the in-hospital mortality rate among
Medicare beneficiaries treated with LRN, although still
uncommon, is both substantially higher than that
reported in early case series9-11,30 and 51% greater than
that observed for beneficiaries undergoing ORN. This
finding is particularly noteworthy given the more favor-
able tumor characteristics observed for those patients
treated with LRN. Although less frequent overall among
all patients treated with LRN versus ORN, rates of com-
plications and blood transfusions were actually similar for
both treatment groups among the subset of patients who
died during the index hospitalization. Taken together,
these findings suggest that the relatively higher in-hospital
mortality associated with LRN may be a consequence of
technical factors and/or failure to recognize and address
severe complications in a timely fashion.
This hypothesis is supported, at least indirectly, by
our observation that, in contrast to ORN, rates of in-hos-
pital mortality were significantly higher among patients
treated with LRN by low-volume surgeons or at low-vol-
ume centers. Whereas the general mechanisms underlying
the volume-outcome relation have been proposed to
include hospital staffing levels, access to health services,
processes of care use (eg, preoperative cardiac stress test,
critical care consultation, invasive monitoring use), and
capacity to manage complications,32-34 the observation
that mortality varies with surgeon and hospital volume for
LRN but not ORN points to factors specific to laparo-
scopy. In this context, and because our study coincided
with a period of escalating adoption, the higher in-hospi-
tal mortality among patients treated with LRN suggests
that significant adverse events may, in fact, be more com-
mon during the initial phase (ie, the learning curve) of a
surgeon’s laparoscopic experience.10 Although further
studies are needed to clarify the cascade of events responsi-
ble for this mortality difference, this finding alone high-
lights the need for long-term monitoring of the safety and
comparative effectiveness of novel surgical therapies.
Our findings should be considered in the context of
several limitations. First, studies based on observational
data are vulnerable to confounding by unmeasured factors
that may account for observed differences in outcomes
between treatment groups. With respect to mortality,
however, patients treated with LRN appeared to be more
favorable surgical candidates based on their higher socioe-
conomic position and less aggressive tumor characteris-
tics. Accordingly, it can be argued that any residual
confounding would tend to bias our findings toward the
null. Second, given the limitations of claims data, we
could not assess more conventional measures of
Figure 6. Frequency of postoperative complications and
blood transfusion for (A) all patients and (B) those who died
during the index hospitalization is stratified by surgical
approach. Postoperative complications are based on specific
ICD-9 codes as described in the Methods section.
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postoperative convalescence including pain and return to
work, among others. Nonetheless, the outcomes we did
evaluate reflect quite well the overall acute recovery pro-
cess of patients undergoing surgery for renal cell carci-
noma. Third, because SEER data lacks detailed staging
information, we were able to adjust our models only for
tumor size and local versus regional stage, raising the pos-
sibility for residual differences in disease severity between
the treatment groups. Nonetheless, it is important to note
that our findings did not change substantively when we
limited our analyses to patients with only localized disease
and/or smaller tumors. Fourth, because our sample is
based on Medicare beneficiaries, our findings may not be
generalizable to patients aged65 years. Nonetheless, the
mortality rates reported herein are consistent with previ-
ous population-based analyses that included all adult age
groups.31,35 Fifth, although nationally representative, the
geographic footprints of SEER registries do not include
many centers with substantial laparoscopic experience and
expertise (where mortality rates may be lower than for the
general Medicare population). Importantly, however, our
specific aim was to evaluate the comparative effectiveness
of LRN as it became incorporated widely into clinical
practice (and not to simply reassess these outcomes in
early adopting centers with established expertise). Finally,
although our findings offer valuable insights into the
impact of laparoscopy, additional studies using more con-
temporary data are needed to assess whether these differ-
ences dissipate or persist long after the widespread
diffusion of LRN.
These limitations notwithstanding, our findings
have important implications for surgical oncology prac-
tice. In general, these data support laparoscopy as the
favored approach for most patients undergoing radical
nephrectomy. This minimally invasive technique yields
clear benefits at a population level, including shorter stays
in the hospital and less frequent use of expensive ICU
services. These benefits have been realized, however, at
the apparent cost of increased mortality during an era of
widespread adoption. The latter finding has direct impli-
cations for patient safety during the dissemination of new
surgical techniques. In the case of LRN, urologists were
(and still are) faced with the challenge of obtaining suffi-
cient formal training in the performance of a technically
complex operation with strong external pressures (eg, per-
ceived benefit, competitive necessity, patient preference)
to adopt a technique that has clear benefits for
patients.2,3,25,36,37 This tension may have led some urolo-
gists to adopt LRN after only limited training, thereby
creating an environment where patients were at higher
risk for certain rare, but potentially lethal, adverse
events.37 This concern has been recognized by both the
urology and surgery communities, and, in recent years,
several mentored and simulator-based programs have
been developed to facilitate and enhance training in
laparoscopy.38,39 Nonetheless, despite the existence of
recommended paradigms for laparoscopic training and
credentialing since the early 1990s, training in laparo-
scopy still relies heavily on preceptorship and self-regula-
tion rather than any formal certification process while
credentialing varies by hospitals and generally involves
limited regulatory oversight.40-42
Similar challenges are now being recognized during
the adoption of the robotic platform in surgical oncol-
ogy.41 Although industry offers basic training for robotic
surgery, the benefits of these programs appear to diminish
over time.43 More vigorous training has been shown to
expedite the learning process, transfer technical skill at
a higher rate, and lead to higher retention over the long-
term.39,44-46 To promote the advancement of patient care
through new surgical technologies while also ensuring
patient safety, the American College of Surgeons has
established multiple Accredited Education Institutes to
facilitate transfer of surgical innovation to practicing
surgeons,47-49 similar programs may be beneficial for
urologists and other surgical oncologists who are faced
with the challenge of adopting complex new technologies.
As demonstrated by our findings, surgical innova-
tions (including LRN) often yield real and important ben-
efits for patients. However, there may be unanticipated
consequences associated with widespread adoption,
including potentially avoidable mortality. As such, the
experience with LRN provides a valuable lesson on the
importance of emphasizing patient safety, long-term com-
parative effectiveness research, and enhanced systems for
postgraduate training and credentialing during and after
the introduction of new surgical technologies. Indeed,
these issues may be of paramount concern as urological
oncologists broaden their use of the robotics platform—
especially for more complex procedures such as partial
nephrectomy50—and pursue newer and more advanced
technologies, such as laparoendoscopic single-site surgery
(LESS) and natural orifice transluminal endoscopic
surgery (NOTES).
Conclusion
In this population-based sample, patients treated with
LRN had a lower likelihood of ICU admission and
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prolonged LOS, findings that support the convalescence
benefits of laparoscopy. At the same time, however, the
observation that in-hospital mortality was higher among
patients treated with LRN suggests a potentially unantici-
pated consequence of this minimally invasive technique
and highlights the need for long-term monitoring during
the widespread adoption of new surgical technologies.
CONFLICT OF INTEREST DISCLOSURES
This research was supported by funding from the Edwin Beer
Research Fellowship in Urology and Urology-Related Fields
from the New York Academy of Medicine, the University of
Michigan Comprehensive Cancer Center, and the Agency for
Healthcare Research and Quality (K08 HS018346-01A1) (all to
DCM).
REFERENCES
1. Wilson CB. Adoption of new surgical technology. BMJ.
2006;332:112-114.
2. Rogers E. Diffusion of Innovations. New York, NY: Free
Press; 1995.
3. Escarce JJ. Externalities in hospitals and physician adoption
of a new surgical technology: an exploratory analysis. J
Health Econ. 1996;15:715-734.
4. Barkun JS, Aronson JK, Feldman LS, et al. Evaluation and
stages of surgical innovations. Lancet. 2009;374:1089-1096.
5. A prospective analysis of, 1518 laparoscopic cholecystecto-
mies. The Southern Surgeons Club. N Engl J Med. 1991;324:
1073-1078.
6. Flum DR, Cheadle A, Prela C, Dellinger EP, Chan L. Bile
duct injury during cholecystectomy and survival in medicare
beneficiaries. JAMA. 2003;290:2168-2173.
7. Gouma DJ, Go PM. Bile duct injury during laparoscopic
and conventional cholecystectomy. J Am Coll Surg. 1994;178:
229-233.
8. Failure of extracranial–intracranial arterial bypass to reduce
the risk of ischemic stroke. Results of an international
randomized trial. The EC/IC Bypass Study Group. N Engl
J Med. 1985;313:1191-1200.
9. Wolf JS, Merion RM, Leichtman AB, et al. Randomized
controlled trial of hand-assisted laparoscopic versus open
surgical live donor nephrectomy. Transplantation. 2001;72:
284-290.
10. Dunn MD, Portis AJ, Shalhav AL, et al. Laparoscopic ver-
sus open radical nephrectomy: a 9-year experience. J Urol.
2000;164:1153-119.
11. Oyen O, Andersen M, Mathisen L, et al. Laparoscopic ver-
sus open living-donor nephrectomy: experiences from a pro-
spective, randomized, single-center study focusing on donor
safety. Transplantation. 2005;79:1236-1240.
12. Gill IS, Kavoussi LR, Clayman RV, et al. Complications of
laparoscopic nephrectomy in 185 patients: a multi-institu-
tional review. J Urol. 1995;154(2 pt 1):479-483.
13. Filson CP, Banerjee M, Wolf JS, Ye Z, Wei JT, Miller DC.
Surgeon characteristics and long-term trends in the adoption
of laparoscopic radical nephrectomy. J Urol. [In press].
14. Hankey BF, Ries LA, Edwards BK. The Surveillance, Epide-
miology, and End Results program: a national resource.
Cancer Epidemiol Biomarkers Prev. 1999;8:1117-1121.
15. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF.
Overview of the SEER-Medicare data: content, research
applications, and generalizability to the United States elderly
population. Med Care. 2002;40(8 suppl):IV-3-18.
16. Miller DC, Saigal CS, Warren JL, et al. External validation
of a claims-based algorithm for classifying kidney-cancer sur-
geries. BMC Health Serv Res. 2009;9:92.
17. Diez Roux AV, Merkin SS, Arnett D, et al. Neighborhood
of residence and incidence of coronary heart disease. N Engl
J Med. 2001;345:99-106.
18. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical
comorbidity index for use with ICD-9-CM administrative
databases. J Clin Epidemiol. 1992;45:613-619.
19. Yu W, Ash AS, Levinsky NG, Moskowitz MA. Intensive
care unit use and mortality in the elderly. J Gen Intern Med.
2000;15:97-102.
20. Cooper LM, Linde-Zwirble WT. Medicare intensive care
unit use: analysis of incidence, cost, and payment. Crit Care
Med. 2004;32:2247-2253.
21. Iwashyna TJ. Critical care use during the course of serious
illness. Am J Respir Crit Care Med. 2004;170:981-986.
22. Hollenbeck BK, Dunn RL, Miller DC, Daignault S, Taub
DA, Wei JT. Volume-based referral for cancer surgery:
informing the debate. J Clin Oncol. 2007;25:91-96.
23. Jencks SF, Williams MV, Coleman EA. Rehospitalizations
among patients in the Medicare fee-for-service program. N
Engl J Med. 2009;360:1418-1428.
24. Miller DC, Daignault S, Wolf JS, et al. Hospital character-
istics and use of innovative surgical therapies among patients
with kidney cancer. Med Care. 2008;46:372-379.
25. Miller DC, Saigal CS, Banerjee M, Hanley J, Litwin MS.
Diffusion of surgical innovation among patients with kidney
cancer. Cancer. 2008;112:1708-1717.
26. Iezzoni LI, Daley J, Heeren T, et al. Identifying compli-
cations of care using administrative data. Med Care.
1994;32:700-715.
27. Weingart SN, Iezzoni LI, Davis RB, et al. Use of
administrative data to find substandard care: validation of
the complications screening program. Med Care. 2000;38:
796-806.
28. Lawthers AG, McCarthy EP, Davis RB, Peterson LE, Palmer
RH, Iezzoni LI. Identification of in-hospital complications
from claims data. Is it valid?Med Care. 2000;38:785-795.
29. Novick AC, Campbell SC, Belldegrun A, et al. Guideline
for management of the clinical stage 1 renal mass. American
Urological Association Web site. http://www.auanet.org/con-
tent/guidelines-and-quality-care/clinical-guidelines/main-
reports/renalmass09.pdf.
30. Permpongkosol S, Link RE, Su LM, et al. Complications
of 2,775 urological laparoscopic procedures: 1993 to 2005.
J Urol. 2007;177:580-585.
31. Mitchell RE, Lee BT, Cookson MS, et al. Radical nephrec-
tomy surgical outcomes in the University Health System
Consortium Data Base: impact of hospital case volume, hos-
pital size, and geographic location on 40,000 patients. Can-
cer. 2009;115:2447-2452.
32. Ghaferi AA, Birkmeyer JD, Dimick JB. Complications, fail-
ure to rescue, and mortality with major inpatient surgery in
medicare patients. Ann Surg. 2009;250:1029-1034.
33. Hollenbeck BK, Daignault S, Dunn RL, Gilbert S, Weizer
AZ, Miller DC. Getting under the hood of the volume-out-
come relationship for radical cystectomy. J Urol. 2007;177:
2095-2099; discussion 2099.
Original Article
4192 Cancer September 15, 2011
34. Hollenbeck BK, Wei Y, Birkmeyer JD. Volume, process of
care, and operative mortality for cystectomy for bladder can-
cer. Urology. 2007;69:871-875.
35. Taub DA, Miller DC, Cowan JA, Dimick JB, Montie JE,
Wei JT. Impact of surgical volume on mortality and length
of stay after nephrectomy. Urology. 2004;63:862-867.
36. Sachdeva AK. Acquiring skills in new procedures and tech-
nology: the challenge and the opportunity. Arch Surg. 2005;
140:387-389.
37. Rogers SO, Gawande AA, Kwaan M, et al. Analysis of sur-
gical errors in closed malpractice claims at 4 liability insur-
ers. Surgery. 2006;140:25-33.
38. McDougall EM, Corica FA, Boker JR, et al. Construct va-
lidity testing of a laparoscopic surgical simulator. J Am Coll
Surg. 2006;202:779-787.
39. Kolla SB, Gamboa AJ, Li R, et al. Impact of a laparoscopic
renal surgery mini-fellowship program on postgraduate urol-
ogist practice patterns at 3-year followup. J Urol. 2010;184:
2089-2093.
40. Dent TL. Training, credentialing, and evaluation in
laparoscopic surgery. Surg Clin North Am. 1992;72:1003-
1011.
41. Zorn KC, Gautam G, Shalhav AL, et al. Training, creden-
tialing, proctoring and medicolegal risks of robotic urologi-
cal surgery: recommendations of the society of urologic
robotic surgeons. J Urol. 2009;182:1126-1132.
42. Schwartz BF. Training requirements and credentialing for
laparoscopic and robotic surgery–what are our responsibil-
ities? J Urol. 2009;182:828-829.
43. Colegrove PM, Winfield HN, Donovan JF, See WA. Lapa-
roscopic practice patterns among North American urologists
5 years after formal training. J Urol. 1999;161:881-886.
44. Cadeddu JA, Wolf JS, Nakada S, et al. Complications of
laparoscopic procedures after concentrated training in uro-
logical laparoscopy. J Urol. 2001;166:2109-2111.
45. Shalhav AL, Dabagia MD, Wagner TT, Koch MO, Linge-
man JE. Training postgraduate urologists in laparoscopic
surgery: the current challenge. J Urol. 2002;167:2135-2137.
46. Gamboa AJ, Santos RT, Sargent ER, et al. Long–term im-
pact of a robot assisted laparoscopic prostatectomy mini fel-
lowship training program on postgraduate urological practice
patterns. J Urol. 2009;181:778-782.
47. Statements on emerging surgical technologies and the evalu-
ation of credentials. American College of Surgeons. Surg
Endosc. 1995;9:207-208.
48. Statement on issues to be considered before new surgical
technology is applied to the care of patients. Committee on
Emerging Surgical Technology and Education, American
College of Surgeons. Bull Am Coll Surg. 1995;80:46-47.
49. Pellegrini CA, Sachdeva AK, Johnson KA. Accreditation of
education institutes by the American College of Surgeons: a
new program following an old tradition. Bull Am Coll Surg.
2006;91:8-12.
50. Van Poppel H, Da Pozzo L, Albrecht W, et al. A prospec-
tive randomized EORTC intergroup phase 3 study compar-
ing the complications of elective nephron–sparing surgery
and radical nephrectomy for low-stage renal cell carcinoma.
Eur Urol. 2007;51:1606-1615.
Radical Nephrectomy Outcomes/Tan et al
Cancer September 15, 2011 4193
